HomeCompareBIOR vs GBDC

BIOR vs GBDC: Dividend Comparison 2026

BIOR yields 909.09% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOR wins by $8252627.36M in total portfolio value
10 years
BIOR
BIOR
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full BIOR calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — BIOR vs GBDC

📍 BIOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIORGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOR + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOR
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, BIOR beats the other by $5,766,862,020,325.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOR + GBDC for your $10,000?

BIOR: 50%GBDC: 50%
100% GBDC50/50100% BIOR
Portfolio after 10yr
$4126334.53M
Annual income
$3,392,288,227,395.69/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

BIOR
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-109.2
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOR buys
0
GBDC buys
0
No recent congressional trades found for BIOR or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIORGBDC
Forward yield909.09%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$8252648.21M$20.85M
Annual income after 10y$6,784,560,004,057.53$16,450,733.83
Total dividends collected$8138900.96M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: BIOR vs GBDC ($10,000, DRIP)

YearBIOR PortfolioBIOR Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$101,609$90,909.09$12,492$1,791.70+$89.1KBIOR
2$972,011$863,288.79$16,527$3,160.58+$955.5KBIOR
3$8,758,157$7,718,105.75$23,588$5,904.90+$8.73MBIOR
4$74,364,546$64,993,317.91$37,141$11,901.65+$74.33MBIOR
5$595,318,755$515,748,691.06$66,205$26,463.38+$595.25MBIOR
6$4,495,664,203$3,858,673,134.79$137,452$66,612.65+$4495.53MBIOR
7$32,043,550,537$27,233,189,840.42$342,372$195,298.53+$32043.21MBIOR
8$215,696,715,677$181,410,116,602.38$1,053,292$686,954.33+$215695.66MBIOR
9$1,372,045,052,584$1,141,249,566,809.58$4,111,439$2,984,416.95+$1372040.94MBIOR
10$8,252,648,210,323$6,784,560,004,057.53$20,849,974$16,450,733.83+$8252627.36MBIOR

BIOR vs GBDC: Complete Analysis 2026

BIORStock

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Full BIOR Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this BIOR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOR vs SCHDBIOR vs JEPIBIOR vs OBIOR vs KOBIOR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.